{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:51:21Z","timestamp":1791093081005,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.critrevonc.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T03:01:58Z","timestamp":1401850918000},"page":"123-132","source":"Crossref","is-referenced-by-count":50,"title":["Adrenocortical carcinoma: The management of metastatic disease"],"prefix":"10.1016","volume":"92","author":[{"given":"Andr\u00e9 P.","family":"Fay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Elfiky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela H.","family":"Tel\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kaymakcalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-3973","authenticated-orcid":false,"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"March","key":"10.1016\/j.critrevonc.2014.05.009_bib0005","first-page":"i","article-title":"Third national cancer survey: incidence data","volume":"41","year":"1975","journal-title":"National Cancer Institute Monograph"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2014.05.009_bib0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2006-923808","article-title":"Adrenocortical carcinoma \u2013 improving patient care by establishing new structures","volume":"114","author":"Koschker","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"July (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.20624","article-title":"Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil","volume":"47","author":"Pianovski","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0025","first-page":"91","article-title":"Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation","volume":"43","author":"Figueiredo","year":"2006","journal-title":"J Med Genet"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2014.05.009_bib0030","doi-asserted-by":"crossref","first-page":"E2238","DOI":"10.1210\/jc.2012-2374","article-title":"Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment","volume":"97","author":"Sirianni","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"April (17)","key":"10.1016\/j.critrevonc.2014.05.009_bib0035","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"August (24)","key":"10.1016\/j.critrevonc.2014.05.009_bib0045","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"October (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1530\/eje.1.02004","article-title":"Molecular genetics of adrenocortical tumours, from familial to sporadic diseases","volume":"153","author":"Libe","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2014.05.009_bib0055","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1210\/jc.2002-021069","article-title":"The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors","volume":"87","author":"Koch","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"April (1\u20132)","key":"10.1016\/j.critrevonc.2014.05.009_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","article-title":"Genetics and epigenetics of adrenocortical tumors","volume":"386","author":"Lerario","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"October (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00268-001-0030-7","article-title":"Adrenal cortical carcinoma","volume":"25","author":"Dackiw","year":"2001","journal-title":"World J Surg"},{"issue":"November (5)","key":"10.1016\/j.critrevonc.2014.05.009_bib0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.eururo.2011.07.062","article-title":"Contemporary management of adrenocortical carcinoma","volume":"60","author":"Zini","year":"2011","journal-title":"Eur Urol"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0085","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0039-6060(97)90229-4","article-title":"Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma","volume":"122","author":"Bellantone","year":"1997","journal-title":"Surgery"},{"issue":"December (8)","key":"10.1016\/j.critrevonc.2014.05.009_bib0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","article-title":"Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma","volume":"6","author":"Schulick","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"June (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0100","first-page":"963","article-title":"An eleven-year experience with adrenocortical carcinoma","volume":"112","author":"Pommier","year":"1992","journal-title":"Surgery"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2014.05.009_bib0110","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1245\/s10434-012-2358-7","article-title":"Resection of adrenocortical carcinoma liver metastasis: is it justified?","volume":"19","author":"Gaujoux","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0115","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0120","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/BF03346675","article-title":"Response to radiation therapy in adrenocortical carcinoma","volume":"33","author":"Hermsen","year":"2010","journal-title":"J Endocrinol Invest"},{"issue":"August (5)","key":"10.1016\/j.critrevonc.2014.05.009_bib0125","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2010.04.030","article-title":"Adjuvant and definitive radiotherapy for adrenocortical carcinoma","volume":"80","author":"Sabolch","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00104-011-2193-6","article-title":"German adrenocortical carcinoma registry, Surgical therapy results and follow-up treatment","volume":"83","author":"Reibetanz","year":"2012","journal-title":"Chirurg"},{"issue":"August (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3109\/02841867609131965","article-title":"Radiation therapy of adrenal cortical carcinoma","volume":"15","author":"Percarpio","year":"1976","journal-title":"Acta Radiol Ther Phys Biol"},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00000421-199104000-00015","article-title":"Radiation therapy for adjunctive treatment of adrenal cortical carcinoma","volume":"14","author":"Markoe","year":"1991","journal-title":"Am J Clin Oncol"},{"issue":"July (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/1097-0142(197907)44:1<239::AID-CNCR2820440139>3.0.CO;2-R","article-title":"Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases","volume":"44","author":"King","year":"1979","journal-title":"Cancer"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0150","first-page":"926","article-title":"Adrenal cortical carcinoma \u2013 a continuing challenge","volume":"94","author":"Henley","year":"1983","journal-title":"Surgery"},{"issue":"July (13)","key":"10.1016\/j.critrevonc.2014.05.009_bib0155","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer"},{"issue":"June (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1677\/erc.1.1315","article-title":"Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines","volume":"15","author":"Cerquetti","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"February (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"issue":"April (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1148\/radiol.2311031007","article-title":"Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results","volume":"231","author":"Mayo-Smith","year":"2004","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.05.009_bib0175","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000200804","article-title":"A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization","volume":"82","author":"Soga","year":"2009","journal-title":"Urol Int"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0180","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jvir.2010.05.020","article-title":"Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma","volume":"21","author":"Cazejust","year":"2010","journal-title":"J Vasc Interv Radiol"},{"issue":"May (9)","key":"10.1016\/j.critrevonc.2014.05.009_bib0185","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"issue":"July (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0190","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CAD.0b013e328300542a","article-title":"Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies","volume":"19","author":"Fareau","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2014.05.009_bib0195","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0200","first-page":"1488","article-title":"Comment \u2013 is there a role for low doses of mitotane (o,p\u2032-DDD) as adjuvant therapy in adrenocortical carcinoma?","volume":"84","author":"Barzon","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0205","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8","article-title":"Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2014.05.009_bib0210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-53-4-672","article-title":"Chemotherapy of adrenocortical cancer with o,p\u2032 DDD","volume":"53","author":"Bergenstal","year":"1960","journal-title":"Ann Intern Med"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0215","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1590\/S0100-879X2000001000008","article-title":"Clinical results of the use of mitotane for adrenocortical carcinoma","volume":"33","author":"Kasperlik-Zaluska","year":"2000","journal-title":"Braz J Med Biol Res"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0220","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0225","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/PL00002218","article-title":"Therapy of the adrenocortical carcinoma with Lysodren (o,p\u2032-DDD). Therapeutic management by monitoring o,p\u2032-DDD blood levels","volume":"96","author":"Heilmann","year":"2001","journal-title":"Med Klin"},{"issue":"June (23)","key":"10.1016\/j.critrevonc.2014.05.009_bib0230","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0235","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p\u2032DDD, o,p\u2032DDA, and o,p\u2032DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"December (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1677\/erc.0.0060529","article-title":"Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma","volume":"6","author":"Seki","year":"1999","journal-title":"Endocr Relat Cancer"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2014.05.009_bib0245","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","article-title":"The treatment of adrenocortical carcinoma with o,p\u2032-DDD: prognostic implications of serum level monitoring","volume":"20","author":"van Slooten","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"October (Suppl. 7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0255","first-page":"vii","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-11-0557","article-title":"High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up","volume":"166","author":"Mauclere-Denost","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"June (23)","key":"10.1016\/j.critrevonc.2014.05.009_bib0265","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMe078087","article-title":"Adjuvant mitotane therapy of adrenal cancer \u2013 use and controversy","volume":"356","author":"Schteingart","year":"2007","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"July (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0275","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0025-7125(16)32365-3","article-title":"Treatment of adrenocortical carcinoma with o,p\u2032-DDD","volume":"56","author":"Hoffman","year":"1972","journal-title":"Med Clin N Am"},{"issue":"December (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0280","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0285","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00268-001-0031-6","article-title":"Cytotoxic treatment of adrenocortical carcinoma","volume":"25","author":"Ahlman","year":"2001","journal-title":"World J Surg"},{"issue":"June (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0290","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2014.05.009_bib0295","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0300","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.3.CO;2-V","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer","volume":"83","author":"Berruti","year":"1998","journal-title":"Cancer"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0305","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2032DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"issue":"June (23)","key":"10.1016\/j.critrevonc.2014.05.009_bib0310","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0315","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0320","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12672-011-0087-1","article-title":"Metronomic therapy concepts in the management of adrenocortical carcinoma","volume":"2","author":"Berruti","year":"2011","journal-title":"Horm Cancer"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2013.08.023","article-title":"Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines","volume":"382","author":"Germano","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"August (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0330","doi-asserted-by":"crossref","first-page":"xiii","DOI":"10.1016\/j.hoc.2011.06.001","article-title":"Renal cell carcinoma","volume":"25","author":"Choueiri","year":"2011","journal-title":"Hematol Oncol Clin N Am"},{"issue":"May (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1758834010361470","article-title":"Updates on novel therapies for metastatic renal cell carcinoma","volume":"2","author":"Courtney","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"December (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0340","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0192623308326151","article-title":"Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors","volume":"36","author":"Patyna","year":"2008","journal-title":"Toxicol Pathol"},{"issue":"September (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0345","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1677\/ERC-10-0082","article-title":"Endocrine side effects of broad-acting kinase inhibitors","volume":"17","author":"Lodish","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.critrevonc.2014.05.009_bib0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2014.05.009_bib0355","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0360","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0365","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"May (15)","key":"10.1016\/j.critrevonc.2014.05.009_bib0370","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"July (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.05.009_bib0380","series-title":"Annual meeting proceedings (post-meeting edition), 25","article-title":"Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma: results of pre-clinical studies","author":"Fassnacht","year":"2007"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0385","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.critrevonc.2014.05.009_bib0390","series-title":"Annual meeting proceedings (post-meeting edition), 25","article-title":"A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)","author":"Samnotra","year":"2007"},{"issue":"March\u2013April (2B)","key":"10.1016\/j.critrevonc.2014.05.009_bib0395","first-page":"1303","article-title":"Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas","volume":"17","author":"Edgren","year":"1997","journal-title":"Anticancer Res"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2014.05.009_bib0400","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s10637-012-9811-0","article-title":"Clinical development of insulin-like growth factor receptor \u2013 1 (IGF-1R) inhibitors: at the crossroad?","volume":"30","author":"Gombos","year":"2012","journal-title":"Invest New Drugs"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2014.05.009_bib0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tem.2012.04.001","article-title":"The next generation of therapies for adrenocortical cancers","volume":"23","author":"Kirschner","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"March (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0410","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0415","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2014.05.009_bib0420","first-page":"15s","article-title":"Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors","volume":"28","author":"Carden","year":"2010","journal-title":"J Clin Oncol"},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0425","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"November (1\u20132)","key":"10.1016\/j.critrevonc.2014.05.009_bib0430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2012.08.014","article-title":"Efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma","volume":"364","author":"Doghman","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"Jun (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0435","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/ERC-11-0270","article-title":"The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells","volume":"19","author":"De Martino","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"September (18)","key":"10.1016\/j.critrevonc.2014.05.009_bib0440","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-10-2979","article-title":"Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer","volume":"17","author":"Naing","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"August (1)","key":"10.1016\/j.critrevonc.2014.05.009_bib0445","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-013-9878-1","article-title":"Everolimus therapy for progressive adrenocortical cancer","volume":"44","author":"Fraenkel","year":"2013","journal-title":"Endocrine"},{"issue":"August (15)","key":"10.1016\/j.critrevonc.2014.05.009_bib0450","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1242\/dev.021493","article-title":"Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex","volume":"135","author":"Kim","year":"2008","journal-title":"Development"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2014.05.009_bib0455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1349-7006.2003.tb01424.x","article-title":"Tumor formation by genetic mutations in the components of the Wnt signaling pathway","volume":"94","author":"Kikuchi","year":"2003","journal-title":"Cancer Science"},{"issue":"August (4)","key":"10.1016\/j.critrevonc.2014.05.009_bib0460","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.CR0070024","article-title":"The Wnt\/beta-catenin signaling pathway as a target in drug discovery","volume":"104","author":"Takahashi-Yanaga","year":"2007","journal-title":"J Pharmacol Sci"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2014.05.009_bib0465","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1210\/jc.2008-0247","article-title":"The T cell factor\/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells","volume":"93","author":"Doghman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"June (2)","key":"10.1016\/j.critrevonc.2014.05.009_bib0470","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2014.05.009_bib0475","article-title":"Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03","volume":"31","author":"Garc\u00eda-Donas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2014.05.009_bib0480","article-title":"A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition","volume":"31","author":"Northfelt","year":"2013","journal-title":"J Clin Oncol"},{"issue":"October (19)","key":"10.1016\/j.critrevonc.2014.05.009_bib0485","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","article-title":"A phase I study of sunitinib plus bevacizumab in advanced solid tumors","volume":"15","author":"Rini","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T03:37:58Z","timestamp":1565494678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1040842814000882"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.05.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}